Aptose Biosciences appoints EY as auditor and receives additional $1.5M from Hanmi for tuspetinib

Aptose Biosciences Inc.

Shareholders voted 96.95% in favor of appointing Ernst & Young LLP as independent registered public accounting firm.
Received an additional US$1.5M advance from Hanmi Pharmaceutical under the existing US$8.5M loan facility.
Total advances under the loan facility now US$7.1M to support clinical development of tuspetinib.
Funds will be used to continue development of tuspetinib-based triple drug frontline therapy for newly diagnosed AML.

item 5.07item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.